This trial is evaluating whether Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg will improve 26 primary outcomes in patients with Alcohol Drinking. Measurement will happen over the course of On each Test Day (1-3), from baseline (prior to drug administration) to the Go No-Go assessment conducted immediately after the targeted BAL is reached during the alcohol infusion..
This trial requires 10 total participants across 3 different treatment groups
This trial involves 3 different treatments. Dexmedetomidine (DEX) For Sublingual (SL) Administration (BXCL501) - 40µg is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
There are an estimated 43 million binge drinking in the United States over one year. These numbers represent a significant problem in modern American life.
Alcohol consumption may be a risk factor for developing cancers of the oral cavity, esophagus, pharynx and larynx. Alcohol intake contributes to a significant proportion of oral cancer cases and some types of oropharyngeal cancer are particularly closely associated with alcohol consumption. There is clear evidence for an increased risk of developing cancers of the larynx, oesophagus and stomach among regular consumers of alcoholic beverages.
Drinking for alcohol reasons is a significant and neglected health problem and represents a health risk as well as an economic burden. Considering its rarity, it should not be cured; instead the problem should be understood as a health risk and prevented by modifying the environment or limiting alcohol consumption to special circumstances (e.g., medical treatment).
Individuals drinking are more likely to be obese and less likely to be fit than non-drinking men. On the other hand, alcoholics are less likely to be athletic and to be fit.
Findings from a recent study highlights the need to understand and prevent alcohol-related problems among parents and their children in order to prevent further alcohol drinking.
Alcoholics tend to be undertreated or undertreated for alcohol abuse issues in general. Recent findings of this survey suggest that clinicians may have more insight into alcohol use in younger patients but fail to adequately counsel individuals who tend to delay therapy until they fail to abstain.
Although there are a number of new treatments for alcoholism, the fact remains that many people are still suffering with the disease for a long time. As more treatments are discovered, it will remain a challenge to find a new cure for alcohol abusing patients. [http://www.withpower.com/medical-dietetics/diabetes-alcohol.aspx, http://www.withpower.com/personal-medicine/diabetes-alcohol.aspx].
We observed that alcohol drinkers are more than twice as likely to drink alcohol with relatives than nonrelatives. Moreover, drinking and heavy drinking are more common in relatives than nonrelatives.
The study reported was the preliminary analysis of the first randomized, double-blind, placebo-controlled study to demonstrate the safety and effectiveness of the sublingual formulation of dextramede(dex) in patients undergoing ambulatory anesthesia for routine surgical procedures.
Dex in all doses of at least 20 mg/kg/24 hr administered to 2x as many as 3 sl doses every 4 hr in combination with sl buprenorphine was found to improve outcomes in patients with opioid-dependent opioid-dependent patients who were transitioning to detoxification or were experiencing withdrawal symptoms.
Recent findings suggest that dexmedetomidine has a positive impact on quality of life. Recent findings suggest that the combination of sl x 40µg dex is effective in treatment of alcohol drinkers.
Dex is safe in the SL formulation of bxcl501. It is well tolerated with few side effects. Dex has a short onset time when administered sublingually, which is helpful for patients and caregivers.